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hjz@zju.edu.cn (JAbstract The present work was focused on the study of the three-dimensional (3D) structural
requirements for the highly potent bioactivity of dipeptidyl peptidase (DPP) IV’s inhibitor. At ﬁrst,
molecular dynamic and mechanic (MD/MM) simulations were performed to research the
conformations of the potent DPP IV’s inhibitor 5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-(3,5-
dimethoxy-phenyl)pyrimidin-4-amine. Using the MD/MM-determined molecular conformers as
templates, the 3D quantitative structure activity relationship (QSAR) studies were carried out
based on a set of arylmethylamine DPP IV inhibitors with the comparative molecular ﬁeld analysis
(CoMFA) approach. The best 3D-QSAR model was constructed with good statistic values of rcv
2
and R2 using PLS analyses (CoMFA: rcv
2 ¼0.660, R2¼0.953). The generated 3D-QSAR model was
proved to be reliable by internal and external validations. Docking studies were further performed
to analyze the interaction mode between the highly potent or low potent arylmethylamine
derivatives and DPP IV. Our ﬂexible docking results also conﬁrmed the possible bioactive
conformation obtained from the 3D-QSAR model, of arylmethylamine-based DPP IV inhibitors.
The 3D-QSAR model may provide information of pharmacophoric features for further design and
optimization of new scaffold compounds with high inhibitory activity to DPP IV.
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Diabetes mellitus is a principle and growing public health
problem in the world. It was estimated that the number of
people suffering from diabetes would increase to 300 million
by 20251. Currently, the oral monotherapy or combination
therapeutics with other drugs are main methods to aid in the
control of diabetes by using all kinds of available antidiabetic
agents in the clinical anti-diabetes therapy2. However, these
agents are considered to be induction of severe adverse effects
and chronic complications3,4. Such a situation promotes
people to develop novel antidiabetic drug with good potency
and low toxicity.
Dipeptidyl peptidase IV (DPP IV) is a serine protease that
cleaves an endogenous oligopeptide at the second residue, which
is the typical amino acid of alanine or proline, from its N-
terminus5. The peptidic hormone glucagon-like peptide 1 (GLP-
1) is one kind of such oligopeptides degradated by DPP IV
protease. GLP-1 plays an important role in the regulation of
insulin release to control the level of blood sugar in human
body6,7. Several studies have demonstrated that the inhibition of
DPP IV can increase the amount of circulating GLP-1 to
improve the secretion of insulin in the body8,9. Therefore, it
has been regarded as an attractive and promising target to
develop novel drug for the treatment of type 2 diabetes. So far, a
couple of identiﬁed DPP IV inhibitors, such as sitagliptin and
saxagliptin, have been approved to be used clinically as anti-
diabetic drugs by FDA10–13. However, there is still a need for
more potent, selective and safer DPP IV inhibitor, which does
not have the inspeciﬁcity and side effect possessed by the
presently available inhibitors14, because of worldwide problem
of type 2 diabetes. Therefore, it is reasonable for researcher to
put a lot of efforts to study the new DPP IV ligands for the
development of the novel anti-diabetes drug.
In the past few years, a large number of compounds were
synthesized and evaluated as DPP IV inhibitors, including
peptidomimetic series and non-peptidomimetic series2. So far,
the SAR and QSAR studies were mainly focused on the
peptidomimetic series. Actually, a couple of ligand-based
models have been constructed to clarify the structure–
activity relationship of peptidomimetic inhibitors of DPP IV.
For example, Zeng et al.15 developed 3D-QSAR models on a
series of ﬂuoropyrrolidine amides to investigate the interaction
between DPP IV’s inhibitors and their receptor by using
comparative molecular ﬁeld analysis (CoMFA) and compara-
tive molecular similarity indices analysis (CoMSIA) methods.
3D-QSAR method was also applied for building a predictive
model based on a series of triazolopiperazine amides as DPP
IV inhibitors16. In these 3D-QSAR studies, the lowest energy
conformation of compound was directly searched to be a
template for structural alignment. Although this methodology
offers an appropriate molecular superimposition, it is still a
doubt whether the conformation with global minimum energy
was an exactly bioactive one. Moreover, these generated 3D-
QSAR models were not applicable for ligands with different
binding modes. On the other hand, QSAR studies have not
been reported to the non-peptidomimetic series of DPP IV’s
inhibitors, which can be an attractive point guiding us to
design novel DPP IV inhibitors.
In the present study, a series of arylmethylamino derivatives,
which were developed to be potent DPP IV inhibitors17, were
used to generate a 3D-QSAR model for non-peptidomimeticcompounds using the CoMFA approach. For such a purpose,
33 compounds were selected from literature17 and divided into
a training database and a test database. Among them, a highly
potent arylmethylamine compound 5-(aminomethyl)-6-(2,4-
dichlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine
(27) was ﬁrst chosen to do MD/MM modeling for its possible
local minimum conformations. Each of MD/MM simulated
conformation was applied to be a starting conformational
template for structural alignments of the compounds in both
training and test databases. Partial Least-Squares (PLS) ana-
lyses were then performed to get cross-validated rcv
2 and no-
cross-validated R2 describing statistical correlation between
inhibitors’ bioactivities and their CoMFA-calculated electro-
static and steric ﬁelds based on their conformations. The
bioactive conformation of ligand was derived by improving
the squared correlation coefﬁcient rcv
2 on the basis of Partial
Least-Squares analyses18. A good 3D-QSAR model was pro-
duced with rcv
2 bigger than 0.6. The generated 3D-QSAR model
was also evaluated by its prediction of bioactivities of com-
pounds in both training and test databases. Our result eluci-
dated structural requirements for enhancing ligand’s bioactivity
to inhibit DPP IV. Furthermore, the ﬂexibly docking simula-
tions were performed to reveal the interaction mode between
inhibitors and DPP IV. The docking results demonstrated that
the binding conformation of arylmethylamino derivative was
congruent with the one obtained from the CoMFA studies. Our
research indicated that the established QSAR model could be
reliable in identifying potential lead compounds with DPP IV
inhibitory activity. The CoMFA contoured trends for the steric
and electrostatic ﬁelds can be used as guides for the generation
of a consistent pharmaocphore model employed for in silico
search new chemical scaffold of DPP IV’s inhibitor. The
corresponding 3D-QSAR model provides a means for predict-
ing the bioactivity of untested compound.2. Methods
2.1. Data preparation
The quality of the biological data under investigation as well as
the structural diversity of the data set is important foundations
for successful 3D-QSAR studies. In the present work, total 33
DPP IV inhibitors were collected from literature published by
Peters et al.17 to do the 3D-QSAR studies using the method of
comparative molecular ﬁeld analysis. Table 1 lists their chemical
structures and corresponding inhibitory IC50 data. Fig. 1 illus-
trates the common structure of pyrimidine core of the selected
arylmethylamino derivatives with different substituent groups,
including methyl, methoxyl, halogenic, trifoloromethyl groups,
on the phenyl rings B or C. These substituent groups have
different hydrophobic and electrostatic properties. Furthermore,
all of the compounds have signiﬁcant variation of their IC50
values ranging seven orders of magnitude, which would be useful
to generate a good 3D-QSAR model. Their inhibitory values
were converted into the corresponding pIC50 (-logIC50) values to
be used as dependent variables in the CoMFA study. The
compounds of the training and test sets were carefully selected
in order to ensure appropriate property coverage on the entire
range of pIC50 values. As listed in Table 1, the data set was
divided into a training set of 27 compounds, enclosing com-
pounds 1–27, for the 3D-QSAR model construction and a test
Table 1 Molecular structures and bioactivity IC50 values of arylmethylamine-based DPP IV inhibitors in the training set
(compounds 1–27) and test set (compounds 28–33) used to construct the 3D-QSAR model.
Compound R IC50 (mM) Compound R IC50 (mM)
1 H 42 18 m-Cl 0.24
2 o-Me 1.5 19 m-OMe 0.34
3 o-Cl 2.5 20 m-CF3 0.13
4 o-OMe 1.5 21 p-Cl 0.053
5 o-F 14 22 p-OMe 0.10
6 m-Me 20 23 p-F 0.0002
7 m-Cl 31 24 p-CF3 0.18
8 m-OMe 80
25
 10
9 m-F 40
26
 0.003
10 m-CF3 170
27
 0.0001
11 p-OMe 47 28 o-CF3 14
12 p-F 18 29 p-Me 1.0
13 p-CF3 1.1 30 p-Cl 1.4
14 H 0.01 31 m-Me 0.0009
15 o-Me 1.75 32 m- F 0.0002
16 o-OMe 0.35 33 p-Me 0.09
17 o-F 0.047
N
N
NH 2 NH 3
1
*
4
2
3
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
*
*
*
*
*
A
B C
** RR'
Figure 1 Common structure of arylmethylamino derivatives. The
atoms for alignment are marked with an asterisk.
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model validation based on the principle of structural diversity.
Since the 8-amine group was reported to have direct interaction
with two acid residues, E205 and E206, of DPP IV, the amino
group of all compounds in both training and test sets was applied
to be in protonation state for our generation of 3D-QSAR
model. The highly potent compound 27 was chosen as the
template molecule for the later structural alignment in our
CoMFA analysis.2.2. Computer molecular modeling
Molecular modeling was carried out using Tripos Sybyl mole-
cular modeling package19,20. MD/MM simulations were ﬁrst
Chaoyi Jiang et al.414performed to sample the compound 27’s conformations at the
local minima of the energy landscape with the Tripos force ﬁeld
and Gasteiger–Hu¨ckel atomic charges. Initially, the Sybyl/Sketch
module was applied for building a starting conformation of
compound 27. The energy optimization process was then
completed to get its local stable conformer with a distance-
dependent dielectric function and a convergence criterion of
0.001 kcal/mol/A˚. MD simulations were performed to mimic the
movement of molecular fragments at the temperature of 2,000 K
with the time length of 300 ps and the step of 1 fs. Total 300
snapshots were collected at a rate of 1 snapshot per ps. Each
snapshot was ﬁnally optimized with the procedures and para-
meters as mentioned in the previous publication21 to get the
conformation at the local minima energy.
Based on each of compound 27’s conformations obtained
from MD/MM simulations, conformations of other com-
pounds in both training set and test set were constructed by
modifying corresponding substitution group R listed in
Table 1 using the molecular fragments library provided within
Sybyl 1.3. These obtained conformers of each compound
were then energy-minimized using the same parameters as
compound 27’s minimization.
2.3. Structural alignment
Since there is a critical requirement of structure alignment in
CoMFA analysis to generate a 3D-QSAR model, the align-
ment rule remains to be a crucial and controversial process in
3D-QSAR analyses. Because of the closely structural similar-
ity of compounds in our CoMFA studies, all of the com-
pounds in both training set and test set were assumed to
interact with DPP IV through the same binding motifs. Each
MD/MM simulated conformation of compound 27 was
regarded as a structural template for the molecular super-
imposition because of its highly inhibitory activity to DPP IV.
On the basis of the common structure and the reported SAR
analyses of the arylmethylamino derivates as DPP IV inhibi-
tors17, it was chosen of the heavy atoms on the aromatic rings
A, B, and C, respectively, illustrated in Fig. 1, for the
structural alignment. It is reasonable to assume that inhibitors
do not necessarily binding to DPP IV in their global minimum
energy conformations because some degree of bond rotation
may be required to adapt electrostatic and H-bonding dis-
tances that would have their good interaction. Therefore, MD/
MM simulated conformation of all compounds were regarded
as a starting points and single bond rotations were allowed to
all of compounds in our studies for a good structural
alignment. On the other hand, it is important to note that
the permitted pharmacophoric conformations of different
compounds must be restricted to those that can be obtained
upon bind within reasonable energy limits. It was acceptable
of a 10 kcal/mol cutoff difference between the local minimum
and the aligned conformational energy of each compound
upon single bond rotation for superimposition21.
2.4. CoMFA Partial Least-Squares analysis
After structural alignment of molecules in the training set, the 3D-
QSAR models were generated using the CoMFA program of
Sybylx1.320. CoMFA analyses were performed for each combina-
tion of steric and electrostatic ﬁelds calculated according to themolecular conformation. All of the molecules in the training set
were placed in a rectangular grid box with the size of extension of
4 A˚ to all compounds in the X, Y, and Z directions of Cartesian
coordinate system. The steric and electrostatic (AM1 charge) ﬁeld
energies were computed using a probe atom of sp3 hybridized
carbon atom with þ1 charge and a distance-dependent dielectric
constant in all of regularly grid space (2.0 A˚). Both steric and
electrostatic cutoffs were set to the default 30 kcal/mol. PLS
analysis was then carried out to generate quantitative relationship
between bioactive values (pIC50) and steric and electrostatic ﬁelds
using default parameters in Sybyl/CoMFAmodule. The minimum
column ﬁltering was set as 2.0 kcal/mol to improve the signal-to-
noise ratio. The optimum number of components was determined
through Leave-One-Out procedure. The ﬁnal model (non-cross-
validated conventional analysis) was developed to produce the no
validated correlation coefﬁcient R2 using the optimum number of
component obtained from the model with the highest cross-
validated rcv
2 .
2.5. Docking studies of interaction between arylmethylamine
derivative and DPP IV
Flexible docking calculation was further carried out to simulate
the interaction mode between arylmethylamino derivative and
DPP IV. For such a purpose, two compounds, the highly potent
compound 23 and the low potent compound 10, were chosen
to do docking simulation using the FlexiDock module of
Sybyl 6.919. The X-ray co-crystal structure of the compound
27-DPP IV complex was obtained from the Protein Data Bank
(entry 1RWQ). The arylmethylamino derivative 23 or 10 was
individually put into the binding cavity of DPP IV to replace the
bound ligand 27 in the co-crystal structure of complex. A binding
pocket was then deﬁned to enclose all of the amino acid residues
within 4 A˚ radius sphere centered by the docked compound in
the initial compound-DPP IV complex. In the continued docking
process, all of the single bonds of residues’ side chains within the
deﬁned DPP IV binding pocket were regarded as rotatable or
ﬂexible bonds, and the docked compound 23 or 10 was allowed
to rotate on all single bonds and move ﬂexibly within the
tentative binding pocket. The atomic charges were recalculated
using the Kollman all-atom approach for DPP IV and the
Gasteiger–Hu¨ckel approach for the docked compound 23 or 10.
The H-bonding sites were marked for suitable atoms, which are
able to act as H-bond donors or acceptors, of both ligand and
residues within the deﬁned DPP-IV active site region. According
to Sybyl/Flexidock method19, the binding interaction energy was
calculated to include the terms of van der Waals, electrostatics,
and torsion energy deﬁned in the Tripos force ﬁeld. The structure
optimization was performed for 50,000-generations using a
genetic algorithm, and the 20 best-scoring ligand–protein com-
plexes were kept for further analyses. The structure with lowest
energy was selected as a ﬁnal model to analyze the composition
of key amino acid residues of DPP IV involved in the interaction
with its inhibitor.3. Results and discussion
3.1. Molecular modeling
Fig. 2 illustrates six representative conformations of com-
pound 27 obtained from MD/MM simulations. MD/MM
Figure 2 Molecular graphic representation of six favored conformations of compound 27 on the basis of the energy minimization of
structures occurring along the molecular dynamics trajectory.
Figure 3 F120-based structural alignment of compounds in the
training set and test set.
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low-energy conformations of compound 27. Dynamic motions
were simulated at temperature of 2,000 K to look for the
probability of inducing conformational transitions past any
possible high-energy barrier. The dynamic simulations were
performed with time steps of 1 fs for 300 ps, and the data were
recorded at 1 ps intervals to get a total of 300 frames. MM
energy minimizations were then carried out for each of these
300 conformers. All 300 conformers were then superimposed
with each other. The conformations with root mean square
(RMS) less than 1.0 A˚ were classiﬁed into the same structural
family. This operation resulted in a convergence of these 300
conformers into six families represented in Fig. 2 by six local
minimum-energy conformations which were sampled during
the MD simulation and then followed by energy minimization.
The energy difference of these six conformers is less than
2 kcal/mol. All of these conformations are potentially present
in the nature.
3.2. CoMFA analyses of arylmethylamine-based derivatives
binding to DPP IV
On the basis of MD/MM simulated conformations of com-
pound 27, the CoMFA method was employed to build a good
3D-QSAR model for arylmethylamino derivatives based on
their observed inhibitory activities (IC50 values) for the DPP
IV receptor. Although the co-crystal structure of compound
27 with DPP IV has been resolved to determine its bioactive
conformation, it would be needed of verifying that this
bioactive conformation would be only one for the generation
of a good 3D-QSAR model with the conformation-based
CoMFA studies. For such a purpose, the MD/MM simulated
conformers F099, F102, F120, F255, F281, and F290 of
compound 27 were individually selected to be an initial
template for the structural alignment of all compounds in
the training set. In the alignment schemes, several variations
were considered by superimposing the common or similar
pharmacophore features, which were detailed in the section of
Methods. Although it has been reported of the co-crystal
structure of 27 with DPP IV, it would helpful to induce
structural requirement for DPP IV inhibitor by comparingdifferent 3D-QSAR model based on each of 27’s potential
conformation obtained from MD/MM simulation. Such pro-
tocol would also make us to characterize 27’s bioactive
conformation interacting with DPP IV by its conformation
analyses and to lead more clues for the drug design of novel
DPP IV’s inhibitor. The best results involved not only a
reasonably good overlap of the relevant pharmacophoric
groups but also statistically signiﬁcant 3D-QSAR models
from CoMFA analyses. For example, Fig. 3 shows the 3D
view of corresponding structural alignment of compounds in
the training set of compounds using conformation F120 as a
structural template.
In all instances, cross-validated PLS analyses were run to
determine the optimal number of components in the model
and to evaluate the robustness of the model based on how well
it predicts data. Table 2 lists the cross-validation rcv
2 values and
corresponding optimum component numbers in all CoMFA
analyses on the basis of the six conformers, respectively, of
compound 27. There is a generally accepted criterion for
CoMFA statistical validity of 0.7Zrcv
2 Z0.6 and optimal
component from 3 to 5 for the PLS method. Our results
indicated that the PLS analysis only based on F120 exceeded
Table 2 Cross-validated analyses of the CoMFA models based on six conformers of compound 27 as structural templates.
No. Template conformation rcv
2 Optimal component
1 F099 0.757 6
2 F102 0.572 5
3 F120 0.660 4
4 F255 0.703 4
5 F281 0.665 1
6 F290 0.814 4
Table 3 Experimental (obsd) and CoMFA-predicted
(pred) pIC50 values of molecules in both training set and
test set.
DPP IV CoMFA model
R2 0.953
Standard error of
estimate
0.390
F 111.180
Compound pIC50
(obsd)
pIC50
(pred)
Residual
1 4.38 4.32 0.06
2 5.82 6.03 0.20
3 5.60 5.45 0.15
4 5.82 5.69 0.14
5 4.85 4.89 0.04
6 4.70 4.11 0.59
7 4.51 4.16 0.35
8 4.10 3.96 -0.14
9 4.40 4.32 0.08
10 3.77 4.32 0.55
11 4.33 4.78 0.45
12 4.74 5.27 0.52
13 5.96 5.99 0.03
14 8.00 8.16 0.16
15 5.76 5.76 0.00
16 6.46 6.25 0.21
17 7.33 7.91 0.58
18 6.62 7.21 0.59
19 6.47 6.37 0.10
20 6.89 6.54 0.34
21 7.28 7.39 0.12
22 7.00 7.16 0.16
23 9.70 8.73 0.97
24 6.74 6.40 0.34
25 5.00 5.05 0.05
26 8.52 8.55 0.03
27 10.00 10.01 0.01
28 4.85 5.73 0.88
29 6.00 6.48 0.48
30 5.85 6.55 0.69
31 9.05 9.03 0.02
32 9.70 8.99 0.71
33 7.05 6.54 0.51
Chaoyi Jiang et al.416this criterion, thus the predictions obtained with this model
was reliable. The non-cross-validated PLS analysis gave a
good correlation coefﬁcient R2 of 0.953 with the training set of
compounds. In the generated CoMFA model, the contribu-
tions of steric and electrostatic ﬁelds were 0.819 and 0.181,
respectively. Furthermore, other six compounds in test set
were used to validate the CoMFA model. The non-cross-
validated PLS analysis was also performed including all of
compounds in both training set and test set. It conferred a
good correlation coefﬁcient R2 of 0.941 with a standard error
of estimate (SEE) of 0.390. F-value stands for the degree of
statistical conﬁdence on the developed models and the model
has good value of 111.18. At the same time, the generation of
consistent statistical models depends on the proper selection of
both training and test sets in terms of structural diversity and
property values distribution. The values of pIC50 from training
set and test set span approximately seven orders of magnitude
and are acceptably distributed across the pIC50 range values.
The derivative of arylmethylamine-based DPP IV inhibitors
has substantial structural diversity. The ring B and ring C have
variously different substituent groups. From the original data
set of 33 inhibitors, 27 compounds (1–27, Table 1) were
selected as members of the training set for model construction,
and the other 6 compounds (28–33, Table 1) as members of
the test set for external model validation, in the ratio of about
4:1 (approximately 20%). Table 3 lists the CoMFA-calculated
pIC50 values of total 33 compounds, showing a good linear
relationship. On the basis of the appropriate representation of
chemical diversity and distribution of property values
(Table 1), the training and test set meet the requirements for
the purpose of internal and external model validation. Fig. 4
illustrates the good correlation between experimental and
CoMFA model-predicted bioactivities of compounds in both
training set and test set. The high R2 reﬂect robustness of the
models, devoid of any chance factors. Therefore, it is a good
3D-QSAR model generated on the basis of conformer F120 of
compound 27, and it can be used to predict the bioactivity of
unknown compound. F120 could be the preferred conforma-
tion of compound 27, which is assumed to be a bioactive
conformation of arylmethylamine compounds to interact with
DPP IV. As discussed lately, F120 is actually consistent to the
one of compound 27 in the crystal structure of complex with
DPP IV. Moreover, when the conformer F120 with highest rcv
2
was generated and validated, it can be used as criteria to solve
the problem of other compounds’ spatial orientations to make
sure that the results of 3D-QSAR are reliable and credible.
Fig. 5 illustrates CoMFA-generated contour maps of both
steric (A) and electrostatic (B) ﬁelds around compound 27. The
contour maps reveal that essential regions in the steric and
electrostatic ﬁelds around ligand might affect the binding ofarylmethylamine derivatives in the active pocket of DPP IV. As
shown in Fig. 5A, the green polyhedrons characterize the regions
where a steric bulky group would increase bioactivity, whereas
yellow contours depict regions where steric substituent would not
be tolerated. Favored and disfavored levels of steric ﬁeld are
Figure 4 Plots of predicted versus experimental pIC50 values of training and test set for the CoMFA model.
Figure 5 CoMFA contour maps for the (A) steric ﬁeld: Green/ yellow contours indicate regions where steric bulky groups increase/
decrease activity. Favored and disfavored levels of these displayed ﬁelds are ﬁxed at 75% and 15%, respectively. (B) electrostatic ﬁeld:
Red/blue contours indicate regions where negative charge increase/decrease activity. Favored and disfavored levels of these displayed
ﬁelds are ﬁxed at 93% and 7%, respectively.
3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors 417ﬁxed at 75% and 25%, respectively. On the other hand, the blue
or red contours in Fig. 5B indicate the regions of favored
positively or negatively charged, respectively, function group
would increase inhibitory activity of ligand for DPP IV. Favored
and disfavored levels of electrostatic ﬁeld are ﬁxed at 93% and
7%, correspondingly. The abundance of the red–blue region to
the yellow–green region points out that electrostatic properties
have more signiﬁcant impact on DPP IV binding potency than
the steric properties. This result is consistent with the statistical
data of the contributions of steric and electrostatic ﬁelds
mentioned above.
As shown in Fig. 5A, the yellow polyhedra areas are
primarily present around para-site in 3-phenyl ring (ring B)
attaching to the pyrimidine ring A, indicating that these areas
would prefer a small branch rather than a bulky substituent. It
is cleared that compound 23 is more bioactive than compound21 because of the different size of the ﬂuoro- and chloro-
groups. We can also make the similar conclusion by compar-
ing the bioactivities of compound 23 and compounds 22 and
24. Fig. 5A also illustrates a large yellow contour around the
ortho position of ring B. Comparing compounds 14 and 17,
introducing a bulky substituent such as methyl and methoxyl
(compounds 15 and 16) would decrease bioactivity. At mean
time, this contour also indicates inducing a bulky group might
lose a ligand’s bioactivity, of 1-amino and 6-methylamino
groups. On the contrary, a small green region around the para-
position of the phenyl ring C indicates that a steric bulky
group at the corresponding position would enhance the
inhibitory activity. For example, compound 14 has the pIC50
value of 8.00 with the steric-favored 2,4-dichlorine group on
the phenyl ring C but compound 1 has the pIC50 value of 4.38
without any substituent on the ring C. It also demonstrates
Chaoyi Jiang et al.418that this region would prefer a bulky group with the fact that
compound 29 (pIC50¼6.00) with a p-methyl group on the 5-
phenyl ring shows better inhibitory activity for DPP IV than
compound 12 (pIC50¼4.74) with a p-F moiety. It is indeed
consistent with the results obtained from the previous studies
that the bulky group occupied a hydrophobic S1 pocket of
DPP IV with a large volume22.
In the electrostatic contour maps shown in Fig. 5B, the red
contour is next to the substituent around meta and ortho
position of the ring B. It implies that a negative charge within
these areas of molecules would increase the binding afﬁnity.
This could explain why compound 23 with a ﬂuorine group on
the 3-phenyl ring B is more potent than compound 33 with a
p-CH3 group on the ring B. On the other hand, a red contour
near ring C indicates that introduction of the relatively
negative groups would be favorable to the molecular bioac-
tivity. This hypothesis is clearly demonstrated by a compar-
ison of bioactivities of compounds 15–24. Among these
compounds, the ones having a halogen atom or –CF3 group
in ring C usually show higher bioactivity than ones with
methyl or methoxyl group. In addition, it is obvious that a
large blue contour is around on the pyrimidine ring A. We can
deduce the similar results according to the later docking
simulation of inhibitor-DPP IV interaction with the electron-
deﬁcient moieties, such as amino or methylamino group, can
make good interaction with the important residues, such as
Glu205 and Glu206. These results can make sure that the
conformations of other compounds which were generated
from compound 27 are reasonable and close to the bioactive
conformations. Meanwhile, the good linear relationship and
the CoMFA-generated contour maps also show that the 3D-
QSAR methods can reﬂect the good relationship of bioactive
data between known and unknown effectively.Figure 6 The docking simulated interaction modes of high
potent compound 23 (A) and low potent compound 10 (B),
respectively. In the mean time, the CoMFA-generated conforma-
tions (red colored) of these compounds were superimposed onto
their docked conformations individually. The superimposition
indicates the molecular conformations in 3D-QSAR model are
consistent with the docking ones.3.3. Docking analyses of arylmethylamine-based derivatives
binding to DPP IV
Fig. 6A illustrates the docking simulated 3D structural model
of compound 23-DPP IV complex by using Sybyl/FlexiDock
module19. In this ﬁgure, the amino acid residues in DPP IV
were displayed with a ‘‘ball-sticks’’ mode and the docked
compound was exhibited with a ‘‘sticks-only’’ style. In the
mean time, the important residues were labeled to have direct
interaction with inhibitor. The docking results indicate that
the best score is 4,493 kcal/mol for the DPP IV-compound
23 interaction, incorporating the sum of the van der Waals,
electrostatics, and torsional energy terms within the Tripos
force ﬁeld. Fig. 6A represents the most stable binding
conformation of compound 23 well docked into the active
pocket of DPP IV. The simulated model of compound 23-DPP
IV complex indicated the hydrophobic and hydrophilic inter-
actions present between ligand and enzyme. The –NH2 group
of compound 23 can form two H-bonds to the oxygen atoms
of carboxyl group of Glu205 with the bond lengths and angles
of 2.252 A˚, 160.871 and 2.924 A˚, 146.431, respectively. Another
two H-bond interactions are also formed between protons of
the methylamino group and oxygen atoms of the carboxyl
functional group in both amino acids of Glu205 and Glu206
with the bond lengths and angles of 2.045 A˚, 151.371 and
2.026 A˚, 122.991, respectively. These H-bond interactions
reveal that the residues Glu205 and Glu206 play critical rolesin the binding of arylmethylamine derivatives to the DPP IV
enzyme. Furthermore, our docking results also indicate that
the cation-p interaction is present between Arg125 and the
compound’s pyrimidine ring A with a distance of 3.823 A˚.
The 2, 4-dichlorophenyl group insert into the hydrophobic
S1 pocket, which is composed by the residues Ser630,
Tyr631, Val656, Trp659, Tyr662, Tyr666 and Val711.
Although the co-crystal structure of compound 27-DPP IV
has been published17, the interaction mode of compound
27-DPP IV was also simulated by using Sybyl/FlexiDock
to evaluate the docking results of arylmethylamine- based
derivatives binding to DPP IV. The interaction score is
4,699 kcal/mol for the interaction of compound 27-DPP
IV. The simulated interaction mode of compound 27-DPP IV
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inhibitory potency of compound 23 is close to 27, since the
docking results show that compound 23 ﬁt very well to the
binding pocket of DPP IV like compound 27.
Fig. 6B illustrates the docking simulated 3D structural
model of low potent compound 10 binding to DPP IV. The
FlexiDock results indicate that the best score is -4,319 kcal/
mol for the DPP IV-compound 10 interaction, incorporating
the sum of the van der Waals, electrostatics, and torsional
energy terms in the Tripos force ﬁeld. Although the interaction
mode between compound 10 and DPP IV is like to the
docking results of compound 27-DPP IV, the former interac-
tion energy is obviously weaker than latter one from the score
result of FlexiDock. Furthermore, there is also a noticeable
difference between compound 27 or 23 and 10 in the S1 pocket
position. The torsion of ring C of compound 27 is 104.81 at
C6-C5-C16-C21 while the torsion of ring C of compound 10 is
88.51 (compound 23 is 103.91). Moreover, the ring C of
compound 23 with a p-Cl substituent group on ring C can
stretch into the S1 pocket, which encloses couples of aromatic
ring-contained residues, like Tyr631, Trp659, Tyr662, and
Tyr666, deeper than the ring C of compound 10. Because
p-Cl is a hydrophobic group, it can improve the hydrophobic
interaction between the ring C and the S1 pocket. By contrast,
there is no hydrophobic group in the p-position of ring C in
compound 10 which may decrease the hydrophobic interaction
between the ring C and S1 pocket. This result can explain why
the potency of compound 10 is lower than compound 27, even
compound 23 reasonably. For the inhibition of DPP IV, it is
vital of whether the relevant substituting group on the ring C
can ﬁt the S1 pocket very well. In the mean time, since a
hydrophilic 12-CF3 group is attached to the ring C of
compound 10, its phenyl ring C is pushed out from pocket
S1 to have less hydrophobic interaction with lipophilic
residues in the pocket S1 of DPP IV than compound 27 or
23 in their docking simulated complexes with DPP IV. It may
inﬂuence the inhibitory activity of compound 10 to DPP IV.
Comparing the docking simulated 3D structures of com-
pounds 10 and 23, the conformation of substituting group at
S1 pocket should be paid more attention when to design new
DPP IV inhibitors. From these results, it is concluded that the
consistency between the QSAR and binding conformations is
high. It is reasonable that the conformations of the modiﬁed
compounds are advisable.3.4. Comparison of the generated 3D-QSAR model and the
docking model
In order to examine the reliability of 3D-QSAR model
obtained from the previous CoMFA studies of the DPP IV
inhibitors, we superimposed the conformation of compound
23 from 3D-QSAR model (red one) onto its docked one
(colored one) as shown in the Fig. 6A. The results indicate that
the 3D-QSAR model is congruent with the results of docking
simulation very well. As it is observed from the superimposi-
tion, there is a general correlation between the conformation
of compound used in the generated QSAR model and its best
docking-simulated binding conformation. For example,
RMSD values between these two conformations were calcu-
lated to be 0.246 A˚ for compound 23 when superimposing
its conformation in the generated 3D-QSAR model anddocking-simulated one by all heavy atoms. However, it should
be noted that some small differences have been observed to
orientations of the phenyl ring C in compound 23 between
these conformations. The torsion angle C6–C5–C16–C21 is
84.71 in QSAR conformation, while it is 103.91 in the binding
conformation. It is reasonable to hypothesize that a ligand
may not have its global minimum energy conformation to
bind on its receptor protein. It is because the lowest energy
ligand-protein complex would be formed under some degree of
bond rotations required to form suitable electrostatic and H-
bonding interaction between protein and ligand.
In Fig. 5A, the CoMFA yellow contours appearing around
methylamino and amino groups indicate that a steric bulky
substituent might have negative effect on the bioactivity of the
ligands. As shown in Fig. 6A, our docking results illustrate a
narrow space around the acidic residues of Glu205 and
Glu206, which can form tight H-bond interactions with
methylamino and amino groups as discussed in the previous
section. Therefore, there is unnecessary modiﬁcation for both
methylamino and amino groups in arylmethylamine-based
DPP IV inhibitors. Similarly, the green contour appearing
around the phenyl ring C approaches the lipophilic region
near S1 pocket, which plays an important role in suppressing
the ability of DPP IV when it is occupied by hydrophobic
group. It suggests that a bulkier group will increase the
biological activity of an inhibitor. By comparing Figs. 5B
and 6A, it can also be concluded that molecular electrostatic
contribution in the generated 3D-QSAR model is consistent to
the electrostatic interaction mode from the docking simulation
of the complex between arylmethylamine derivatives and DPP
IV. For example, blue colored contour maps are oriented
towards the electronegative groups of DPP IV’s acidic residues
like Glu205 and Glu206. The blue contour around the
methylamino and amino groups covers the space enclosing
the residues of Glu205 and Glu206 which are acidic amino
acids. The potency of inhibitor can be increased while
electropositive groups are introduced, since the H-bond or
salt bridge interaction can be formed between the –NH2
groups and the carboxyl group of Glu205 and Glu206.
Moreover, the blue contour around the ring A points to the
residue of Tyr547 mainly because of the –OH group of Tyr547
which is a polar group. Equally no modiﬁcation was made in
the pyrimidine ring which is an alkalescent group, so it is
reasonable to present a large blue contour below the ring A.
Furthermore, there are red contours present around the ring
B. Considering the surrounding polar amino acids, like Ser552
and Gln553, it is reasonable that the same effect would be
obtained whether electropositive or electronegative groups
are added.
Therefore, the performed docking studies not only highlight
the consistency between the QSAR and binding conformations
but also provide the knowledge about crucial interactions with
the active site of DPP IV for enhanced activity. In this study,
we preferred to generate energy minimized conformation(s),
get bioactive conformations by 3D-QSAR method and vali-
date the method through the docking model. Because the
conformations generated by QSAR methods are consistent
with bound conformations. It is convinced that through
QSAR and docking methods, we can ﬁnd some relationship
between energy minimized conformation and bound confor-
mation. At the same time, these results also validated that the
bioactive conformation can be generated by QSAR studies.
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for us to explain the difference between the conformation and
inhibition, which can lead us to further design new compounds
reported in our patent application 23, with high potentially
inhibitory activity for DPP IV.4. Conclusions
The global purpose of this work is to produce a 3D-QSAR
model for the prediction of arylmethylamine analogs. We
report here the ﬁrst establishment of 3D-QSAR model and
docking model on a series of arylmethylamine-based non-
peptidomimetic DPP IV inhibitor. The constructed models
revealed statistical signiﬁcance and good predictive abilities by
using CoMFA and docking studies. Moreover, on the basis of
the CoMFA model contour maps, signiﬁcant regions for
steric, electrostatic, hydrophobic, H-bond interactions were
identiﬁed to enhance bioactivity. At the same time, CoMFA
studies were combined with the docking results based on the
known X-ray crystal structure of DPP IV to evaluate the
reliability of the generated 3D-QSAR. The correlation of the
results obtained from docking and QSAR studies lead to
better understanding of the structural requirements for
enhanced activity. The obtained results can be used as a
guideline to design and predict new potent DPP IV inhibitors,
which could be an effective way to ﬁnd novel leads for the
development of antidiabetic drug.
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